The company

Neurophoenix is a biopharmaceutical company developing a new therapeutic solution for optic neuropathies, one of the leading causes of blindness worldwide. The company is building a pipeline of novel first-in-class drugs which combine both neuroprotective and neuroregenerative properties.

This new therapeutic approach is based on the research conducted at the Institut Pasteur (Paris) by the Viral Neuro-Immunology team, led by Dr. Monique Lafon.

Neurophoenix was created in August 2018. The company was a laureate and “Grand Prize” of the 2018 i-Lab Innovation Contest organized by the French Ministry of Research.